Page last updated: 2024-12-10

ciprokiren

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

ciprokiren: a renin inhibitor; prevents neointima formation to the same extent as cilazapril [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID5312136
CHEMBL ID2104380
SCHEMBL ID564425
MeSH IDM0227040

Synonyms (13)

Synonym
ciprokiren
(2s)-2-benzyl-n-[(2s)-1-[[(2s,3r,4s)-1-cyclohexyl-4-cyclopropyl-3,4-dihydroxybutan-2-yl]amino]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]-3-(2-methyl-1-morpholin-4-yl-1-oxopropan-2-yl)sulfonylpropanamide
(alphas)-n-((1s,2r,3s)-1-(cyclohexylmethyl)-3-cyclopropyl-2,3-dihydroxypropyl)-alpha-((alphas)-alpha-(((1-methyl-1-(morpholinocarbonyl)ethyl)sulfonyl)methyl)hydrocinnamamido)imidazole-4-propionamide
unii-k259z4o1b3
k259z4o1b3 ,
1h-imidazole-4-propanamide, n-(1-(cyclohexylmethyl)-3-cyclopropyl-2,3-dihydroxypropyl)-alpha-((2-(((1,1-dimethyl-2-(4-morpholinyl)-2-oxoethyl)sulfonyl)methyl)-1-oxo-3-phenylpropyl)amino)-, (1s-(1r*,(r*(r*)),2s*,3r*))-
ciprokiren [inn]
143631-62-3
ro 44-9375
CHEMBL2104380
(.alpha.s)-n-((1s,2r,3s)-1-(cyclohexylmethyl)-3-cyclopropyl-2,3-dihydroxypropyl)-.alpha.-((.alpha.s)-.alpha.-(((1-methyl-1-(morpholinocarbonyl)ethyl)sulfonyl)methyl)hydrocinnamamido)imidazole-4-propionamide
SCHEMBL564425
Q27281849
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's6 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]